Healios KK (JP:4593)
:4593
Want to see JP:4593 full AI Analyst Report?
4593 Stock Chart & Stats
¥370.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥370.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥255.00 - ¥747.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.65M
Market Cap
¥51.03B
Enterprise Value¥36.77B
Total Cash (Recent Filing)¥5.68B
Total Debt (Recent Filing)¥2.61B
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 20, 2026EPS Estimate
-11.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.90
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥965.00Price Target Upside160.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-42.73
Revenue Forecast (FY)¥658.52M
Bulls Say, Bears Say
Bulls Say
Improved LeverageA materially lower debt-to-equity ratio meaningfully reduces near-term financing stress and interest burden. This improved capital structure gives management more flexibility to fund R&D and clinical programs, lowering short-to-medium-term insolvency risk and improving strategic optionality.
Specialized Regenerative PipelineA clear focus on cell therapy and iPSC technologies in ophthalmology and CNS creates durable competitive differentiation and high technical barriers to entry. Specialized expertise and external collaborations support long-term pipeline value and increase chances of clinical/commercial success versus generalist peers.
Modest Revenue GrowthSustained top-line growth, even modest, indicates commercial traction or expanding service/product adoption. For a clinical-stage biotech, revenue expansion helps justify continued R&D investment, supports operating scale benefits over time, and reduces reliance solely on financing to fund activities.
Bears Say
Deep UnprofitabilityPersistently negative gross and operating margins show the business is not covering core costs with current revenue. Over the medium term this erodes equity, forces strategic trade-offs between development and commercialization, and increases dependency on external funding until structural profitability is achieved.
Worsening Cash BurnConsistent negative operating and free cash flow increases financing risk and can lead to dilutive capital raises. For a development-stage biotech, escalating cash consumption constrains the ability to sustain multiple clinical programs and increases execution risk if access to low-cost financing tightens.
Negative Returns On EquityNegative ROE signals that invested capital is not generating shareholder value. Even with lower leverage, persistent losses prevent return improvement, making it harder to attract long-term capital and threatening shareholder dilution or asset rationalization if profitability cannot be restored.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥255.00 and its highest was ¥747.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥51.03B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is May 20, 2026 which is in 30 days.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on Feb 16, 2026. The company reported ¥18.9 earnings per share for the quarter, beating the consensus estimate of ¥4.65 by ¥14.25.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Undervalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -11.14.
How many shares outstanding does Healios KK have?
Healios KK has 135,002,200 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of ¥18.9 in its last earnings report, beating expectations of ¥4.65. Following the earnings report the stock price went up 4.087%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
4593 Stock 12 Month Forecast
Average Price Target
¥965.00
▲(160.81% Upside)
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---